



## ASX Announcement

3 October 2017

### Release of Escrowed Securities

In accordance with ASX Listing Rule 3.10.A, Creso Pharma Limited (“**Creso**” or “**the Company**”) advises that the following securities are due to be released from escrow:

Description	Number	Date of Release
Fully Paid Ordinary Shares	1,000,000	13 October 2017
Performance Shares	1,000,000	13 October 2017
<b>Total</b>	<b>2,000,000</b>	

The Company notes that the securities above are held by Hemp Industries s.r.o, Creso’s Joint Venture partner in Slovakia.

---END---

#### Investor Enquiries:

Gabriella Hold  
M: 0411 364 382  
E: [gabriella.hold@mcpartners.com.au](mailto:gabriella.hold@mcpartners.com.au)

#### Media Enquiries:

Elise Hughan  
M: 0458 855 500  
E: [elise.hughan@mcpartners.com.au](mailto:elise.hughan@mcpartners.com.au)

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney, NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

#### About Creso Pharma

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in medicinal cannabis and cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade nutraceuticals and medicinal cannabis products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.